Bristol Myers Squibb to buy biopharmaceutical firm MyoKardia for $13.1bn
MyoKardia is engaged in the discovery and development of targeted therapies to treat serious cardiovascular diseases. As per terms of the merger deal, BMS subsidiary will begin a